Mariusz Wiglusz

Dr. Mariusz Wiglusz


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2018 in Medical Hypotheses
Verified
Journal Article
Closed access
AWAdam Włodarczyk
Adam Włodarczyk
MWMariusz Wiglusz
Mariusz Wiglusz
WCWiesław Jerzy Cubała
Wiesław Jerzy Cubała

1 March 2019 in Epilepsy & Behavior
Verified
Journal Article
Closed access
MWMariusz Wiglusz
Mariusz Wiglusz
JLJerzy Landowski
Jerzy Landowski
WCWiesław J. Cubała
Wiesław J. Cubała

1 February 2018 in Epilepsy & Behavior
Verified
Journal Article
Closed access
MWMariusz Wiglusz
Mariusz Wiglusz
JLJerzy Landowski
Jerzy Landowski
WCWiesław Jerzy Cubała
Wiesław Jerzy Cubała

1 May 2016 in Epilepsy & Behavior
Verified
Journal Article
Closed access
MWMariusz Wiglusz
Mariusz Wiglusz
JLJerzy Landowski
Jerzy Landowski
LMLidia Michalak
Lidia Michalak
WCWiesław Jerzy Cubała
Wiesław Jerzy Cubała

1 November 2018 in Neurologia i Neurochirurgia Polska
Verified
Journal Article
Closed access
NGNatalia Górska
Natalia Górska
JSJakub Słupski
Jakub Słupski
WCWiesław Jerzy Cubała
Wiesław Jerzy Cubała
MWMariusz Wiglusz
Mariusz Wiglusz
MGMaria Gałuszko-Węgielnik
Maria Gałuszko-Węgielnik
People with epilepsy (PWE) frequently suffer from comorbid mood and anxiety disorders. Depression is one of the major psychiatric comorbidities having a negative impact on the quality of life in people with epilepsy. A review of the literature indicates that the majority of antidepressant-related seizures have been associated with either ultra-high doses or overdosing and, generally, the risk of antidepressant-associated seizures is low. Correspondingly, there is some evidence indicating that antidepressants of most widely used groups may additionally lower the risk of triggering seizures. Four antidepressants are not recommended for patients with epilepsy, i.e.: amoxapine, bupropion, clomipramine and maprotiline. Clinicians applying first line of depression treatment in patients with epilepsy should consider use of SSRIs or SNRIs, particularly sertraline, citalopram, mirtazapine, reboxetine, paroxetine, fluoxetine, escitalopram, fluvoxamine, venlafaxine, duloxetine. Implementation of anticonvulsive drugs in depressed patients should include valproate, carbamazepine, lamotrigine, gabapentin, pregabalin. The paper reviews the evidence for the clinical use of antidepressants in PWE.

1 June 2019 in Epilepsy & Behavior
Verified
Journal Article
Closed access
MWMariusz Wiglusz
Mariusz Wiglusz
JLJerzy Landowski
Jerzy Landowski
WCWiesław J. Cubała
Wiesław J. Cubała